Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated May 14, 2024 (2 years ago)

Moxifloxacin 4 mg/0.8 mL Preservative-Free 0.8mL Single-Use vials…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Moxifloxacin 4 mg/0.8 mL Preservative-Free 0.8mL Single-Use vials for Intraocular Injection, Rx only, Imprimis NJOF, LLC. 1705 Route 46 West, unit 6B, Ledgewood, NJ 07852, NDC 71384-511-08

Affected NDC 71384-0511-08

Compare with the code on your package — it is the most precise check available.

Drug: Moxifloxacin

Recalling firm
Imprimis NJOF, LLC
NDC code
71384-511-08
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0516-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Moxifloxacin recalls

See all

Other recalls by Imprimis NJOF, LLC

All 2024 recalls